AARD vs. ABUS, ARVN, TRVI, ANAB, KALV, VECT, KROS, VALN, PHAR, and ORGO
Should you be buying Aardvark Therapeutics stock or one of its competitors? The main competitors of Aardvark Therapeutics include Arbutus Biopharma (ABUS), Arvinas (ARVN), Trevi Therapeutics (TRVI), AnaptysBio (ANAB), KalVista Pharmaceuticals (KALV), VectivBio (VECT), Keros Therapeutics (KROS), Valneva (VALN), Pharming Group (PHAR), and Organogenesis (ORGO). These companies are all part of the "pharmaceutical products" industry.
Aardvark Therapeutics vs.
Arbutus Biopharma (NASDAQ:ABUS) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, community ranking, earnings, analyst recommendations and dividends.
Aardvark Therapeutics has a net margin of 0.00% compared to Arbutus Biopharma's net margin of -1,137.65%. Aardvark Therapeutics' return on equity of 0.00% beat Arbutus Biopharma's return on equity.
43.8% of Arbutus Biopharma shares are owned by institutional investors. 20.3% of Arbutus Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Arbutus Biopharma received 429 more outperform votes than Aardvark Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Aardvark Therapeutics an outperform vote while only 70.66% of users gave Arbutus Biopharma an outperform vote.
Aardvark Therapeutics has lower revenue, but higher earnings than Arbutus Biopharma.
In the previous week, Arbutus Biopharma and Arbutus Biopharma both had 1 articles in the media. Arbutus Biopharma's average media sentiment score of 1.88 beat Aardvark Therapeutics' score of 0.00 indicating that Arbutus Biopharma is being referred to more favorably in the media.
Arbutus Biopharma currently has a consensus price target of $5.50, suggesting a potential upside of 74.60%. Aardvark Therapeutics has a consensus price target of $31.50, suggesting a potential upside of 350.00%. Given Aardvark Therapeutics' higher probable upside, analysts plainly believe Aardvark Therapeutics is more favorable than Arbutus Biopharma.
Summary
Arbutus Biopharma and Aardvark Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.
Get Aardvark Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AARD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aardvark Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:AARD) was last updated on 4/18/2025 by MarketBeat.com Staff
Buy AARD Stock Free AARD Stock Alerts